A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients

This study has been completed.

Study NCT00001669 Information provided by National Institutes of Health Clinical Center (CC)

First Received: November 3, 1999 Last Updated: March 3, 2008 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	April 2000
Estimated Primary Completion Date:	No date given